chr3-37050588-G-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000249.4(MLH1):c.2206G>T(p.Glu736*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000249.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
not provided Pathogenic:1
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Observed in an individual with colorectal cancer (PMID: 21286823); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 21387278, 30787465, 29345684, 28466842, 21286823, 34897210) -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the MLH1 protein in which other variant(s) (p.Tyr750*) have been determined to be pathogenic (PMID: 10422993, 16338176, 20533529). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This sequence change creates a premature translational stop signal (p.Glu736*) in the MLH1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 21 amino acid(s) of the MLH1 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 21286823). ClinVar contains an entry for this variant (Variation ID: 232190). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.E736* pathogenic mutation (also known as c.2206G>T), located in coding exon 19 of the MLH1 gene, results from a G to T substitution at nucleotide position 2206. This changes the amino acid from a glutamic acid to a stop codon within coding exon 19. This mutation has been identified in individuals with colon cancer including one individual whose tumor demonstrated microsatellite instability (MSI-H) (Roberts ME et al. Genet. Med. 2018 10;20:1167-1174; Lastella P et al. Fam. Cancer 2011 Jun;10:285-95). This mutation has also been seen as a somatic alteration in conjunction with LOH in an MSI-H colorectal tumor demonstrating loss of MLH1 and PMS2 by IHC staining (Haraldsdottir S et al. Nat Commun, 2017 05;8:14755). In addition, structural analysis suggests that this alteration perturbs a known functional domain responsible for binding to and stabilizing PMS2 (Mohd AB et al. DNA Repair (Amst.), 2006 Mar;5:347-61). As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at